21 results on '"Casamitjana R"'
Search Results
2. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.
- Author
-
COSTA, M., SAIZ, A., CASAMITJANA, R., CASTAÑER, M. FERNÁNDEZ, SANMARTÍ, A., GRAUS, F., and JAROUEMADA, D.
- Subjects
GLUTAMATE decarboxylase ,IMMUNOGLOBULINS ,PEOPLE with diabetes - Abstract
SUMMARY Antibodies to glutamic acid decarboxilase (GAD-Abs) are present in the serum of 60–80% of newly diagnosed type 1 diabetes (DM1) patients and patients with autoimmune polyendocrine syndrome (APS) associated with DM1. Higher titre of GAD-Abs are also present in the serum of 60% of patients with stiff-man syndrome (SMS) and all reported patients with cerebellar ataxia associated with polyendocrine autoimmunity (CAPA). Several studies suggest that GAD-Abs may play a critical role in the pathogenesis of SMS and CAPA but little is known about T-cell responsiveness to GAD-65 in these neurological diseases. To analyse cell-mediated responses to GAD, we studied the peripheral blood lymphocyte proliferation and cytokine responses to recombinant human GAD-65 in 5 patients with SMS, 6 with CAPA, 9 with DM1, 8 with APS and 15 control subjects. GAD-65-specific cellular proliferation was significantly higher in SMS than in CAPA, DM1, APS or controls. In contrast, only T cells from CAPA patients showed a significantly high production of interferon-γ after GAD stimulation, compared to all other patients and controls. No differences were found for IL-4 production. These results suggest that, despite similar humoral autoreactivity, cellular responses to GAD are different between SMS and CAPA, with a greater inflammatory response in CAPA, and this difference may be relevant to the pathogenesis of these diseases. [ABSTRACT FROM AUTHOR] more...
- Published
- 2002
- Full Text
- View/download PDF
Catalog
3. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH.
- Author
-
Balasch, Juan, Vidal, Ester, Peñarrubia, Joana, Casamitjana, Roser, Carmona, Francisco, Creus, Montserrat, Fábregues, Francisco, Vanrell, Juan A., Balasch, J, Vidal, E, Peñarrubia, J, Casamitjana, R, Carmona, F, Creus, M, Fábregues, F, and Vanrell, J A more...
- Abstract
Background: It has been recently suggested that gonadotrophin-releasing hormone agonist down-regulation in some normogonadotrophic women may result in profound suppression of LH concentrations, impairing adequate oestradiol synthesis and IVF and pregnancy outcome. The aims of this study, where receiver-operating characteristic (ROC) analysis was used, were: (i) to assess the usefulness of serum LH measurement on stimulation day 7 (S7) as a predictor of ovarian response, IVF outcome, implantation, and the outcome of pregnancy in patients treated with recombinant FSH under pituitary suppression; and (ii) to define the best threshold value, if any, to discriminate between women with 'low' or 'normal' LH concentrations.Methods: A total of 144 infertile women undergoing IVF/intracytoplasmic sperm injection (ICSI) treatment were included. Seventy-two consecutive patients having a positive pregnancy test (including 58 ongoing pregnancies and 14 early pregnancy losses) were initially selected. As a control non-pregnant group, the next non-conception IVF/ICSI cycle after each conceptual cycle in our assisted reproduction programme was used.Results: The median and range of LH values in non-conception cycles, conception cycles, ongoing pregnancies, and early pregnancy losses, clearly overlapped. ROC analysis showed that serum LH concentration on S7 was unable to discriminate between conception and non-conception cycles (AUC(ROC) = 0.52; 95% CI: 0.44 to 0.61) or ongoing pregnancy versus early pregnancy loss groups (AUC(ROC) = 0.59; 95% CI: 0.46 to 0.70). To assess further the potential impact of suppressed concentrations of circulating LH during ovarian stimulation on the outcome of IVF/ICSI treatment, the three threshold values of mid-follicular serum LH proposed in the literature (<1, < or =0.7, <0.5 IU/l) to discriminate between women with 'low' or 'normal' LH were applied to our study population. No significant differences were found with respect to ovarian response, IVF/ICSI outcome, implantation, and the outcome of pregnancy between 'low' and 'normal' S7 LH women as defined by those threshold values.Conclusions: Our results do not support the need for additional exogenous LH supplementation in down-regulated women receiving a recombinant FSH-only preparation. [ABSTRACT FROM AUTHOR] more...- Published
- 2001
- Full Text
- View/download PDF
4. Mid-luteal serum inhibin-A concentration as a marker of endometrial differentiation.
- Author
-
Creus, Montserrat, Ordi, Jaume, Fábregues, Francisco, Casamitjana, Roser, Vanrell, Juan A., Balasch, Juan, Creus, M, Ordi, J, Fábregues, F, Casamitjana, R, Vanrell, J A, and Balasch, J
- Abstract
Background: Recent studies have indicated that the corpus luteum is a major source of circulating inhibin-A and serum concentrations of inhibin-A may reflect the human luteal function. The present prospective study was undertaken to determine the usefulness of mid-luteal serum concentrations of inhibin-A as markers of endometrial receptivity (as assessed by histological dating and alphavbeta3 integrin expression) and whether they are better predictors of endometrial function than serum progesterone.Methods: Consecutive infertile women (experimental group, n = 50) with regular menstrual cycles, and fertile women who were requesting contraception and had regular menstrual patterns and normal secretory endometria (control group, n = 10) were included. In all women basal body temperature, luteal serum concentrations of oestradiol, progesterone, prolactin, and inhibin-A, and endometrial biopsies were used in the same cycle to assess luteal function.Results: Out-of-phase mid-secretory endometria were detected in 17 of the 50 infertile women. Lack of alphavbeta3 integrin expression was detected in 27 of the 50 mid-luteal endometrial biopsies. Thus, hormonal concentrations were compared in the mid-luteal phase between the following eight groups of women: group 1 (n = 10), control fertile women; group 2 (n = 50), infertile women (all); subdivided into group 3 (n = 33), with in-phase biopsies; group 4 (n = 17), with out-of-phase endometria; group 5 (n = 23), expressing alphavbeta3 integrin in endometria; group 6 (n = 27), whose endometria did not express alphavbeta3 integrin; group 7 (n = 18), with both in-phase endometrial biopsy and alphavbeta3 integrin expression; and finally group 8 (n = 12), whose endometria were out-of-phase and did not express alphavbeta3 integrin. Mid-luteal serum concentrations of oestradiol, progesterone, prolactin, and inhibin-A of the seven infertile groups were similar to those of the control group of fertile women. No statistically significant difference between the infertile groups was observed for any hormonal parameter considered.Conclusion: Mid-luteal serum inhibin-A determination does not accurately reflect endometrial function/maturation and it is not a better indicator of endometrial luteal phase dysfunction than mid-luteal serum progesterone. [ABSTRACT FROM AUTHOR] more...- Published
- 2001
- Full Text
- View/download PDF
5. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome.
- Author
-
Creus, Montserrat, Peñarrubia, Joana, Fábregues, Francisco, Vidal, Ester, Carmona, Francisco, Casamitjana, Roser, Vanrell, Juan A., Balasch, Juan, Creus, M, Peñarrubia, J, Fábregues, F, Vidal, E, Carmona, F, Casamitjana, R, Vanrell, J A, and Balasch, J more...
- Abstract
Recent reports investigating the value of basal inhibin B determination as a predictor of ovarian reserve and assisted reproduction treatment have led to discordant results. This study was undertaken to further assess the relative power of day 3 inhibin B and follicle stimulating hormone (FSH) (defined before treatment) and the woman's age both as single and combined predictors of ovarian response and pregnancy in an in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) programme. A total of 120 women undergoing their first cycle of IVF or ICSI was included. Forty consecutive cycles cancelled because of poor follicular response were initially selected. As a control group, the nearest completed IVF/ICSI cycles before and after each cancelled cycle (i.e. the closest cycles in temporal relationship to the index cycle) were used. Mean age and basal FSH concentrations were significantly higher in the cancelled than in the control group (P: < 0.01 and P: < 0.001 respectively), whereas basal inhibin B was significantly higher in the latter (P: < 0.05). The association of basal FSH (with an accuracy or predictive value of ovarian response of 79%) with cancellation rate was significant, independent of, and stronger than the effects of age and inhibin B (P: < 0.05). Any two or all three of these variables studied did not improve the predictive value of FSH alone. Woman's age was the only variable independently associated with pregnancy rate. It is concluded that the stronger predictors of success in patients undergoing their first IVF/ICSI treatment cycle are age and basal FSH rather than inhibin B. Basal FSH concentration was a better predictor of cancellation rate than age, but age was a stronger predictor of pregnancy rate. [ABSTRACT FROM AUTHOR] more...
- Published
- 2000
- Full Text
- View/download PDF
6. Plasma soluble tumor necrosis factor-&agr; receptors circulate in proportion to leptin levels during the menstrual cycle in lean but not in obese women.
- Author
-
Fernández-Real, J. M., Gutierrez, C., Vendrell, J., Casamitjana, R., and Ricart, W.
- Published
- 2000
- Full Text
- View/download PDF
7. Day 5 inhibin B serum concentrations as predictors of assisted reproductive technology outcome in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment.
- Author
-
Peñarrubia, Joana, Balasch, Juan, Fábregues, Francisco, Carmona, Francisco, Casamitjana, Roser, Moreno, Vicenta, Calafell, Josep Ma., Vanrell, Juan A., Peñarrubia, J, Balasch, J, Fábregues, F, Carmona, F, Casamitjana, R, Moreno, V, Calafell, J M, and Vanrell, J A more...
- Abstract
The present study investigates the usefulness of inhibin A, inhibin B and serum oestradiol concentrations obtained in the fifth day of gonadotrophin therapy in predicting ovarian response and assisted reproductive treatment outcome in women undergoing ovarian stimulation under pituitary desensitization. A total of 80 women undergoing their first cycle of in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment were studied. Twenty consecutive cycles which were cancelled because of a poor follicular response were initially selected. As a control group, 60 women were randomly selected from our assisted reproductive treatment programme matching by race, age, body mass index, and indication for IVF/ICSI to those in the cancelled group. For each cancelled cycle, three IVF/ICSI women who met the matching criteria were included. Basal follicle stimulating hormone (FSH) concentrations were significantly higher in the cancelled than in the control group, whereas basal inhibin B was significantly higher in the latter. Basal oestradiol concentrations were similar in both groups of patients. On day 5 of gonadotrophin therapy serum concentrations of oestradiol, inhibin A and inhibin B were significantly lower in the cancelled group as compared with controls. Logistic regression analysis showed that the association for day 5 inhibin B (with a predictive value of ovarian response of 91.03%) with cancellation rate was significant, independent of, and stronger than, the effects of any other hormone variable investigated. In addition, day 5 inhibin B concentrations were correlated directly with parameters of ovarian response, ovum retrieval and oocyte and fertilization outcome. However, day 5 inhibin B was not a better predictor of pregnancy than the other hormone variables studied on this day. It is concluded that inhibin B concentrations obtained early in the follicular phase during ovarian stimulation under pituitary suppression for assisted reproductive treatment are highly predictive of ovarian response. [ABSTRACT FROM AUTHOR] more...
- Published
- 2000
8. Growth hormone does not increase the expression of insulin-like growth factors and their receptor genes in the pre-menopausal human ovary.
- Author
-
Peñarrubia, J, Balasch, J, García-Bermúdez, M, Casamitjana, R, Vanrell, J A, and Hernandez, E R
- Abstract
A growing body of information now supports the existence of a complete intraovarian insulin-like growth factor I (IGF-I) system. Although the precise role of IGF-I in the context of ovarian physiology remains to be determined, it is likely that IGF-I may engage in the amplification of gonadotrophin hormonal action. These facts and experiments with animals establishing the ovaries of multiple species as a site of growth hormone (GH) reception and action have led to the use of recombinant GH (rGH) as an adjunctive agent to potentiate ovulation induction by exogenous gonadotrophins. Whether intraovarian IGF-I plays an intermediary role in GH hormonal action at the ovarian level remains uncertain at present. The aim of this study was to evaluate whether rGH administration to pre-menopausal women could modify the expression of the IGF-I gene in the ovary. The expression of the IGF-I gene was examined in a time-dependent manner in normal pre-menopausal ovaries obtained from nine women treated with rGH and nine control women treated with placebo, using solution hybridization/RNase protection assays. Ovarian tissue samples were obtained 24 h (six women) and 7 days (12 women) following rGH/placebo injection. Total RNA (20 microg) from whole pre-menopausal ovaries (with or without rGH treatment) as well as from human granulosa cells was hybridized with a human IGF-I antisense RNA. IGF-I peptide, but not oestradiol, serum concentrations increased significantly 24 h after rGH injection. IGF-I gene, however, was not expressed in the luteinized granulosa cells and whole pre-menopausal ovaries irrespectively of rGH treatment in ovarian samples analysed both 1 and 7 days following rGH injection. On the contrary, IGF-II mRNA transcribed from the fetal or fetal-neonatal IGF-II promoter and IGF-I receptor mRNA (both used as hybridization control) were both found in whole pre-menopausal ovary and luteinized granulosa cells. Nevertheless, no changes in the hybridization patterns were seen in the absence or presence of rGH. These studies demonstrate that rGH administration to normal premenopausal women does not change the expression of insulin-like growth factors and their receptor genes in the pre-menopausal human ovary. Furthermore, these results provide further evidence against locally produced IGF-I as responsible for any ovarian effects seen in systemic rGH administration. [ABSTRACT FROM AUTHOR] more...
- Published
- 2000
9. Follicular fluid concentrations of adrenomedullin, vascular endothelial growth factor and nitric oxide in IVF cycles: relationship to ovarian response.
- Author
-
Manau, Dolors, Balasch, Juan, Jimenez, Wladimiro, Fabregues, Francisco, Civico, Salvadora, Casamitjana, Roser, Creus, Montserrat, Vanrell, Juan A., Manau, D, Balasch, J, Jiménez, W, Fábregues, F, Civico, S, Casamitjana, R, Creus, M, and Vanrell, J A more...
- Abstract
Marked granulosa cell proliferation along with important changes in the vascular bed of the ovary characterize IVF cycles associated with multiple follicular growth and maturation. The present report investigated follicular fluid (FF) and circulating concentrations of adrenomedullin, vascular endothelial growth factor (VEGF) and nitric oxide (NO) in 70 IVF patients (14 of whom became pregnant); these three vasoactive substances may be implicated in extensive ovarian tissue remodelling. Serum and FF concentrations of oestradiol and progesterone were also measured in the 70 IVF cycles studied. Follicular fluid concentrations of VEGF and adrenomedullin but not nitrite/nitrate (the two stable oxidation products of NO metabolism) were significantly higher (P < 0.0001) than the corresponding circulating concentrations. Follicular fluid concentrations of oestradiol and progesterone were not correlated with those of adrenomedullin, VEGF or nitrite/nitrate. No relationship existed between circulating concentrations of adrenomedullin, VEGF or nitrite/nitrate on the day of oocyte aspiration and parameters of ovarian response to gonadotrophin stimulation. In contrast, FF adrenomedullin concentration showed a direct relationship with day 3 FSH serum concentration (r = 0.53, P < 0.01) and the number of ampoules of gonadotrophin administered (r = 0.36, P < 0.005), but an inverse correlation with the total number of oocytes retrieved (r = -0.29, P < 0.01) and the number of mature oocytes (r = -0.25, P < 0. 05). A positive correlation was found for FF VEGF concentration and chronological age (r = 0.29, P < 0.05) and ampoules of gonadotrophins administered (r = 0.30, P < 0.05). There was no relationship between nitrite/nitrate FF concentrations and parameters of ovarian response. Neither serum concentrations nor FF concentrations of adrenomedullin, VEGF or nitrite/nitrate were correlated with IVF outcome. This study suggested for the first time that increased FF concentrations of adrenomedullin can be a marker of decreased ovarian response in IVF. Our results also provide further evidence favouring an association between FF VEGF and patient's age, while on the basis of our findings NO measurements are not a useful marker of ovarian response. [ABSTRACT FROM AUTHOR] more...
- Published
- 2000
- Full Text
- View/download PDF
10. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families.
- Author
-
Costa, A., Bescós, M., Velho, G., Chêvre, J. C., Vidal1, J., Sesmilo1, G., Bellanné-Chantelot, C., Froguel, P., Casamitjana, R., Rivera-Fillat, F., Gomis, R., and Conget, I.
- Published
- 2000
- Full Text
- View/download PDF
11. The role of IGF binding protein-3 as a parameter of activity in acromegalic patients.
- Author
-
Halperin, I., Casamitjana, R., Flores, L., Fernandez-Balsells, M., and Vilardell, E.
- Published
- 1999
- Full Text
- View/download PDF
12. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
- Author
-
Peñarrubia, J, Balasch, J, Fábregues, F, Creus, M, Casamitjana, R, Ballescá, JL, Puerto, B, Vanrell, JA, Ballescá, J L, and Vanrell, J A
- Abstract
Gonadotrophin-releasing hormone agonist (GnRHa)-induced ovulation after gonadotrophin ovarian stimulation is used to prevent ovarian hyperstimulation syndrome and multiple pregnancy in polyfollicular cycles. However, one of the major problems to be resolved is corpus luteum function after follicular maturation and ovulation by mid-cycle GnRHa administration. The present report investigated the luteal phase in non-conceptual polyfollicular cycles in 26 patients (group 1) receiving a single dose of 0.5 mg leuprolide acetate to induce ovulation and in a control group of patients (n = 26) (group 2) who were given human chorionic gonadotrophin (HCG) (10,000 IU i.m.) for ovulation induction. All of them were normal ovulatory women undergoing gonadotrophin ovarian stimulation because of unexplained infertility or male factor. In both groups of patients two doses of 2500 IU HCG i.m. were given 6 and 10 days after the ovulatory dose of HCG or GnRHa to support the luteal phase. All cycles were ovulatory as shown by mid-luteal serum progesterone concentrations >10 ng/ml. Mean serum progesterone concentrations were 62% higher in group 2 than in group 1, but this difference was not statistically significant. The mean length of the luteal phase was similar in groups 1 and 2. It is concluded that HCG luteal support is a useful tool to overcome the luteal phase inadequacy that characterizes GnRHa-triggered cycles after gonadotrophin stimulation. [ABSTRACT FROM AUTHOR] more...
- Published
- 1998
- Full Text
- View/download PDF
13. Integrin expression in normal and out-of-phase endometria.
- Author
-
Creus, M, Balasch, J, Ordi, J, Fábregues, F, Casamitjana, R, Quinto, L, Coutifaris, C, Vanrell, JA, and Vanrell, J A
- Abstract
Integrins have recently been proposed as having a major role in endometrial receptivity. Different patterns of integrin expression have been described during the normal endometrial cycle, and the co-expression of several integrins, mainly α1, α4 and β3 has been considered as specific to the 'window of implantation'. In the present study 55 infertile patients underwent two endometrial biopsies during a single menstrual cycle. An early biopsy was done on postovulatory days 6-8, and a late biopsy was performed on postovulatory days 10 to 12. Histological dating as well as immunohistochemical evaluation of α1, α4, β1, β3, β5, αvβ3 integrin expression and oestrogen and progesterone receptors were determined in all endometrial biopsies. Oestradiol and progesterone serum concentrations in serum were evaluated on the same days of the endometrial samplings. Nine out of the 55 midluteal biopsies (16.4%) showed out-of-phase endometria, but all biopsies were in phase in the late luteal phase. Differences in integrin expression between in- and out-of-phase biopsies were observed only for αvβ3 integrin glandular expression during the midluteal phase. αvβ3 integrin glandular expression was found in all late luteal phase biopsies. αvβ3 expression was closely correlated with histological maturation of the endometrium appearing suddenly at postovulatory day 6-7 and being expressed by all endometria dated as postovulatory day ≥8, irrespective of midluteal endometrial biopsies being in phase or out of phase. No differences in integrin expression were detected between patients with or without endometriosis or between patients who became spontaneously pregnant and those who did not. In conclusion, further studies are necessary before patterns of integrin expression may offer an alternative to predict uterine receptivity and implantation potential. [ABSTRACT FROM PUBLISHER] more...
- Published
- 1998
- Full Text
- View/download PDF
14. Midluteal immunoreactive alpha-inhibin serum concentrations as markers of luteal phase deficiency.
- Author
-
Balasch, J, Creus, M, Fábregues, F, Casamitjana, R, Ordi, J, and Vanrell, J A
- Subjects
BIOPSY ,ENDOMETRIUM ,ESTRADIOL ,GLYCOPROTEINS ,LONGITUDINAL method ,LUTEAL phase ,MENSTRUATION disorders ,PEPTIDES ,PROGESTERONE ,PROLACTIN - Abstract
The present prospective clinical study was undertaken to determine the usefulness of midluteal phase serum immunoreactive alpha-inhibin concentrations as markers of luteal phase deficiency and whether they are better indicators of biopsy confirmed luteal phase defect than serum progesterone. Consecutive patients (n = 138) with regular menstrual cycles attending our Infertility Clinic (experimental group) and 15 fertile women who were requesting contraception and had regular menstrual patterns (control group) were included. In all women (patients and controls), basal body temperature, midluteal serum concentrations of oestradiol, prolactin, progesterone and immunoreactive alpha-inhibin, and premenstrual endometrial biopsy were used in the same cycle to assess luteal function. Out-of-phase secretory endometria were detected in 15 of the 138 patients. Thus, hormonal concentrations were compared between the following three groups of women: group 1 (n = 15), infertile patients with defective secretory endometria; group 2 (n = 123), infertile patients with normal secretory endometria; and controls (n = 15), fertile women with normal secretory endometria. Midluteal serum concentrations of progesterone, immunoreactive alpha-inhibin, oestradiol, and prolactin of the two groups studied were similar to those of the control group of fertile women. Our results indicate that midluteal serum inhibin determination does not accurately reflect histological maturation of the endometrium and it is not a better indicator of endometrial luteal phase deficiency than midluteal serum progesterone concentration. [ABSTRACT FROM AUTHOR] more...
- Published
- 1996
- Full Text
- View/download PDF
15. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.
- Author
-
Balasch, J, Miró, F, Burzaco, I, Casamitjana, R, Civico, S, Ballescá, J L, Puerto, B, and Vanrell, J A
- Abstract
To evaluate the relative importance of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in follicular development and oocyte fertility in the human species, the use of recombinant human FSH, human menopausal gonadotrophin (HMG), and very highly purified urinary human FSH (FSH-HP) plus oestradiol valerate for ovarian stimulation and in-vitro fertilization (IVF) were compared in three cycles in a woman with isolated congenital gonadotrophin deficiency who had never been treated with ovarian stimulating agents. The total number of ampoules of gonadotrophins used was lower in the HMG treatment cycle. Ovarian response and IVF outcome in the three treatment cycles were as follows: (i) HMG cycle: normal follicular growth, normal pattern of oestradiol and inhibin through the menstrual cycle, high fertilization rate (93%); (ii) recombinant FSH cycle: normal follicular growth, low oestradiol and abnormal inhibin, finally poor rate of fertilization (28%); (iii) FSH-HP plus oestradiol valerate cycle: normal follicular growth, normal pattern of inhibin and poor fertilization rate (27%). Luteal plasma progesterone concentrations were much higher in the HMG treatment cycle. This case shows that FSH is the only factor required in order to induce follicular growth in the human, although LH or a product derived from its action may assist in order to achieve full follicular maturity and oocytes capable of fertilization. Though oestradiol might have a mediatory role in the process of follicular maturation, our results favour a direct primary role of LH in complete maturation of the follicle. [ABSTRACT FROM AUTHOR] more...
- Published
- 1995
16. Intra-uterine insemination, cervical pregnancy and successful treatment with methotrexate.
- Author
-
Balasch, Juan, Peñarrubia, Joana, Ballescá, José J., Creus, Montserrat, Casamitjana, Roser, Vanrell, Juan A., Balasch, J, Peñarrubia, J, Ballescá, J L, Creus, M, Casamitjana, R, and Vanrell, J A
- Abstract
Cervical pregnancy is rare but one of the most dangerous of all pregnancy complications. The aetiology of cervical implantation is unclear and because of the fear of profuse haemorrhage abdominal hysterectomy has been historically considered the standard therapy. We report here an unusual case of an infertile woman with cervical ectopic pregnancy after ovulation induction with gonadotrophins and intra-uterine insemination. The patient was successfully treated with parenteral methotrexate without significant morbidity. It is concluded that chemotherapy should be initially considered in most cervical pregnancies either as the sole form of treatment or to improve the chances of success in alternative conservative measures. [ABSTRACT FROM PUBLISHER] more...
- Published
- 1994
17. Transvaginal intratubal insemination, ectopic pregnancy and treatment by single-dose parenteral methotrexate.
- Author
-
Balasch, J, Ballesca, J L, Fábregues, F, Puerto, B, Casamitjana, R, and Vanrell, J A
- Abstract
We report a case of a woman with ectopic pregnancy with fetal cardiac activity after ovulation induction and transvaginal intratubal insemination by tactile sensation. The patient was successfully treated by single-dose methotrexate (MTX) (77 mg or 50 mg/m2 given intramuscularly). Control hysterosalpingograms showed no tubal patency on the involved side. Potential advantages and hazards of transvaginal intratubal insemination and single-dose MTX for ectopic pregnancy are discussed. [ABSTRACT FROM AUTHOR] more...
- Published
- 1992
18. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot.
- Author
-
Balasch, J, Gómez, F, Casamitjana, R, Carmona, F, Rivera, F, and Vanrell, J A
- Abstract
A total of 20 women with regular menstrual cycles normal ovulatory function were randomized to receive 3.75 mg or 1.87 mg of D-Trp-6-luteinizing hormone-releasing hormone (LHRH) in microcapsules either in the early follicular phase (day 2) or during the mid-luteal phase (day 21) of the menstrual cycle. Pituitary--ovarian function was studied by sequential plasma measurements of oestradiol, follicle stimulating hormone, luteinizing hormone and progesterone. Our results show that the full, standard dose (3.75 mg) of D-Trp-6-LHRH depot and the half-dose (1.87 mg) were equally effective in their desensitizing action, and that desensitization occurs more rapidly with early follicular phase administration of the analogue. [ABSTRACT FROM AUTHOR] more...
- Published
- 1992
19. REM sleep behavior disorder and narcoleptic features in anti--Ma2-associated encephalitis.
- Author
-
Compta Y, Iranzo A, Santamaría J, Casamitjana R, and Graus F
- Published
- 2007
20. Role of thyroid hormones on serum leptin levels.
- Author
-
Sesmilo, G., Casamitjana, R., Halperin, I., Gomis, R., and Vilardell, E.
- Published
- 1998
- Full Text
- View/download PDF
21. Rsal Polymorphism of the human growth hormone gene (GH1).
- Author
-
Oriola, J., Casamitjana, R., Nogueès, N., Pageès, R., Romero, M., and Rivera-Fillat, F.
- Published
- 1991
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.